CureVac Shares Catapult 494% Following Successful IPO Debut
The Tübingen-based biotech firm which is one of the eight big startups in Europe in terms of funding, went public last week at $16 per common share and has been …
Read MoreThe Next Generation Biotech Media
The Tübingen-based biotech firm which is one of the eight big startups in Europe in terms of funding, went public last week at $16 per common share and has been …
Read MoreVaccine development is traditionally a slow process, due to the rigorous preclinical testing, lead optimization, and subsequent clinical trials performed on healthy volunteers and patients. Hence the announcement of Russia’s …
Read More(Partner Content) The second installment of the “TAIWAN is Helping: AI x Pandemic Prevention Online Forum,” conducted at the China Medical University on June 20th, featured rousing discussions on topics …
Read MoreOn August 4th, nearly two months since the inception of vaccine testing, Novavax announced preliminary data from its Phase 1 trial. The vaccine produced a promising immune response in the …
Read MoreBy T. Chakraborty, Ph.D. As COVID-19 continues to affect human lives, global biopharmas have initiated collaborations with research organizations to bring forth innovative drugs against it. Immunic Inc., which focuses …
Read MoreBy Pavel Ryzhov, Ph.D. With COVID-19 cases escalating around the world, there is an urgent need for a safe and efficacious vaccine. However, the complexity of the R&D process and …
Read MoreBy Sangeeta Chakraborty, Ph.D. & Sahana Shankar, Ph.D. Candidate In the second “combating pandemics” session at BIO Asia-Taiwan, discussions revolved around ways to prepare the world from future pandemics based …
Read MoreBy Sahana Shankar, Ph.D. Candidate At the BIO ASIA-Taiwan conference, Dr. Hong-Jen Chang, President of Taiwan Research-based Pharmaceutical Manufacturers’ Association (TRPMA), moderated a timely showcase on how Taiwan’s government, healthcare …
Read MoreBy Ruchi Jhonsa, Ph.D. The experimental coronavirus vaccine developed by the University of Oxford, together with pharmaceutical giant AstraZeneca was able to generate strong T cell and antibody immune response …
Read MoreBy Pavel Ryzhov, Ph.D. As COVID-19 cases continue to climb and hover around 14 million, the cry for a vaccine is now higher than ever. However, the exact timeline for …
Read More